Related Experiment Video
Updated: Jan 7, 2026

05:07
Multimodality Diagnosis of Mesenteric Ischemia
Published on: July 21, 2023
1.1K
Semaglutide-induced transient intestinal ischemia: A case report
International Journal of Clinical Pharmacology and Therapeutics
|December 30, 2025
Summary
Wegovy (semaglutide) effectively manages obesity but can cause gastrointestinal issues. This report details an extremely rare case of transient intestinal ischemia after a patient
Area of Science:
- Endocrinology
- Gastroenterology
- Pharmacology
Background:
- Obesity is a significant global health concern.
- Semaglutide, a GLP-1 receptor agonist, is approved for type 2 diabetes (Ozempic) and weight management (Wegovy).
- While generally well-tolerated, Wegovy can cause gastrointestinal adverse effects.
Purpose of the Study:
- To report an extremely rare case of transient intestinal ischemia.
- To highlight a potential, albeit unusual, adverse effect of Wegovy in obesity management.
Main Methods:
- Case report of a 50-year-old male patient.
- Documented adverse event following the first dose of Wegovy.
Main Results:
- The patient experienced transient intestinal ischemia.
- This event occurred shortly after the initial Wegovy dosage.
Conclusions:
- Transient intestinal ischemia is an extremely rare adverse effect associated with Wegovy.
- Further investigation into the mechanisms and incidence of such events may be warranted.
Related Concept Videos
Drugs for Treatment of Diarrhea-Predominant IBS
590
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
590
Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents
397
Acute diarrhea, a common gastrointestinal disturbance, is characterized by the rapid evacuation of fluid stools, leading to an excessive weight in fluid. This condition typically arises from disorders affecting intestinal water and electrolyte transport. It can be triggered by an increased osmotic load within the intestine, excessive secretion of electrolytes and water, mucosal exudation of protein and fluid, or altered intestinal motility. The primary risks of acute diarrhea are dehydration...
397
Drugs for Treatment of Constipation-Predominant IBS
664
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
664
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
849
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
849
Inflammatory Bowel Disease IV: Pharmacological Management
427
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
427
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
604
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
604

